Business Combination - Fair Value of Consideration (Details) - Pharmagesic |
Oct. 07, 2024
USD ($)
|
|---|---|
| Business Combination | |
| Fair value of common stock issued | $ 893,093 |
| Fair value of preferred stock issued | 70,372,634 |
| Total Consideration Paid | $ 71,265,727 |
| X | ||||||||||
- Definition Amount of common stock equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination. No definition available.
|
| X | ||||||||||
- Definition Amount of preferred stock equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination. No definition available.
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Details
|